Overview

Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.
Phase:
Phase 3
Details
Lead Sponsor:
PharmaKing
Treatments:
Oltipraz